Increase of the number of votes in Hansa Biopharma
Lund, Sweden, June 30, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, announced today that the number of outstanding votes in Hansa have increased during the month of June 2022 as a result of the conversion of a total of 114,666 class C shares to a total of 114,666 ordinary shares. The conversion was carried out by Hansa in order to deliver ordinary shares to participants in the company’s incentive program adopted at the annual general meeting in 2019. The total number of votes in Hansa has therefore increased